| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.807 | 0.004 | 0.807 | Psychostimulant | 0.77 0.004 DBMET00626 | ||
| 0.782 | 0.004 | 0.857 | 5 Hydroxytryptamine release stimulant | 0.857 0.003 DBMET00626 | DBMET00626 | |
| 0.635 | 0.005 | 0.635 | Hypolipemic | 0.354 0.034 DBMET00626 | ||
| 0.519 | 0.044 | 0.583 | Analgesic | 0.583 0.03 DBMET00626 | DBMET00626 | |
| 0.494 | 0.024 | 0.494 | Spasmolytic | 0.361 0.049 DBMET00626 | ||
| 0.418 | 0.03 | 0.42 | Vasodilator, coronary | 0.42 0.029 DBMET00626 | DBMET00626 | |
| 0.362 | 0.029 | 0.362 | Angiogenesis stimulant | 0.281 0.057 DBMET00626 | ||
| 0.344 | 0.017 | 0.353 | Tyrosine 3 hydroxylase inhibitor | 0.353 0.015 DBMET00626 | DBMET00626 | |
| 0.369 | 0.066 | 0.413 | Vasodilator, peripheral | 0.413 0.051 DBMET00626 | DBMET00626 | |
| 0.333 | 0.031 | 0.333 | 5 Hydroxytryptamine uptake stimulant | 0.308 0.041 DBMET00626 | ||
| 0.292 | 0.035 | 0.42 | ErbB-1 antagonist | 0.42 0.014 DBMET00626 | DBMET00626 | |
| 0.342 | 0.086 | 0.342 | Toll-Like receptor 7 agonist | |||
| 0.353 | 0.1 | 0.375 | Antibacterial | 0.375 0.088 DBMET00626 | DBMET00626 | |
| 0.299 | 0.048 | 0.299 | Vasodilator | 0.296 0.049 DBMET00626 | ||
| 0.336 | 0.089 | 0.336 | Toll-Like receptor agonist | |||
| 0.372 | 0.127 | 0.394 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.394 0.106 DBMET00626 | DBMET00626 | |
| 0.333 | 0.095 | 0.333 | GABA C receptor rho-3 antagonist | 0.322 0.102 DBMET00626 | ||
| 0.266 | 0.044 | 0.266 | Anesthetic general | 0.148 0.116 DBMET00626 | ||
| 0.321 | 0.103 | 0.697 | Antiobesity | 0.697 0.011 DBMET00626 | DBMET00626 | |
| 0.216 | 0.01 | 0.249 | Antineoplastic alkaloid | 0.249 0.005 DBMET00626 | DBMET00626 | |
| 0.214 | 0.015 | 0.214 | Alpha 2c adrenoreceptor antagonist | 0.17 0.025 DBMET00626 | ||
| 0.34 | 0.154 | 0.354 | Caspase 9 stimulant | 0.354 0.142 DBMET00626 | DBMET00626 | |
| 0.185 | 0.011 | 0.185 | Prolactin inhibitor | 0.138 0.028 DBMET00626 | ||
| 0.265 | 0.096 | 0.273 | Nootropic | 0.273 0.089 DBMET00626 | DBMET00626 | |
| 0.316 | 0.148 | 0.342 | Cyclophilin D inhibitor | 0.342 0.128 DBMET00626 | DBMET00626 | |
| 0.172 | 0.005 | 0.172 | Nicotinic alpha4beta2 receptor antagonist | 0.154 0.007 DBMET00626 | ||
| 0.246 | 0.084 | 0.246 | Gastrin inhibitor | 0.237 0.096 DBMET00626 | ||
| 0.208 | 0.051 | 0.23 | 5 Hydroxytryptamine 3E antagonist | 0.23 0.027 DBMET00626 | DBMET00626 | |
| 0.242 | 0.085 | 0.242 | Interleukin agonist | 0.231 0.093 DBMET00626 | ||
| 0.217 | 0.064 | 0.281 | Nitric-oxide synthase stimulant | 0.281 0.017 DBMET00626 | DBMET00626 | |
| 0.168 | 0.018 | 0.168 | Creatine kinase inhibitor | 0.133 0.032 DBMET00626 | ||
| 0.193 | 0.045 | 0.193 | Acetylcholine M1 receptor antagonist | |||
| 0.17 | 0.023 | 0.283 | Alpha 2 adrenoreceptor antagonist | 0.283 0.009 DBMET00626 | DBMET00626 | |
| 0.18 | 0.038 | 0.18 | Anesthetic local | |||
| 0.18 | 0.038 | 0.18 | Cholinergic antagonist | 0.167 0.044 DBMET00626 | ||
| 0.159 | 0.018 | 0.188 | Acetylcholine nicotinic antagonist | 0.188 0.014 DBMET00626 | DBMET00626 | |
| 0.183 | 0.043 | 0.183 | Toll-Like receptor 9 antagonist | |||
| 0.147 | 0.007 | 0.147 | Acetylcholine M1 receptor agonist | 0.04 0.032 DBMET00626 | ||
| 0.226 | 0.087 | 0.226 | DNA synthesis inhibitor | 0.226 0.088 DBMET00626 | ||
| 0.149 | 0.01 | 0.149 | Acetylcholine muscarinic agonist | 0.051 0.042 DBMET00626 | ||
| 0.174 | 0.039 | 0.174 | Acetylcholine antagonist | 0.163 0.043 DBMET00626 | ||
| 0.156 | 0.027 | 0.161 | EphA2 antagonist | 0.161 0.025 DBMET00626 | DBMET00626 | |
| 0.139 | 0.011 | 0.189 | Dopamine uptake inhibitor | 0.189 0.007 DBMET00626 | DBMET00626 | |
| 0.138 | 0.011 | 0.44 | Adrenaline uptake inhibitor | 0.44 0.004 DBMET00626 | DBMET00626 | |
| 0.158 | 0.033 | 0.158 | Microtubule formation inhibitor | 0.149 0.038 DBMET00626 | ||
| 0.149 | 0.026 | 0.149 | Acetylcholine agonist | 0.091 0.054 DBMET00626 | ||
| 0.155 | 0.032 | 0.155 | Ca2+-transporting ATPase inhibitor | 0.147 0.05 DBMET00626 | ||
| 0.123 | 0.005 | 0.137 | Dopamine D3 agonist | 0.137 0.005 DBMET00626 | DBMET00626 | |
| 0.138 | 0.025 | 0.184 | Alpha 2a adrenoreceptor antagonist | 0.184 0.016 DBMET00626 | DBMET00626 | |
| 0.197 | 0.086 | 0.197 | Antimitotic | |||
| 0.128 | 0.019 | 0.346 | 5 Hydroxytryptamine uptake inhibitor | 0.346 0.005 DBMET00626 | DBMET00626 | |
| 0.133 | 0.03 | 0.133 | Acetylcholine release stimulant | |||
| 0.255 | 0.152 | 0.271 | Histamine release inhibitor | 0.271 0.141 DBMET00626 | DBMET00626 | |
| 0.122 | 0.019 | 0.122 | Dopamine D1 antagonist | 0.065 0.045 DBMET00626 | ||
| 0.201 | 0.098 | 0.201 | Peptidyltransferase inhibitor | |||
| 0.146 | 0.044 | 0.164 | Beta amyloid protein antagonist | 0.164 0.031 DBMET00626 | DBMET00626 | |
| 0.112 | 0.009 | 0.238 | Dopamine transporter inhibitor | 0.238 0.004 DBMET00626 | DBMET00626 | |
| 0.111 | 0.009 | 0.111 | Protein kinase C beta inhibitor | 0.099 0.014 DBMET00626 | ||
| 0.119 | 0.018 | 0.148 | Neuronal nicotinic receptor antagonist | 0.148 0.013 DBMET00626 | DBMET00626 | |
| 0.13 | 0.03 | 0.13 | Acetylcholine M3 receptor agonist | 0.118 0.036 DBMET00626 | ||
| 0.114 | 0.014 | 0.114 | Glycine receptor agonist | 0.101 0.02 DBMET00626 | ||
| 0.103 | 0.006 | 0.103 | Alpha-mannosidase inhibitor | 0.099 0.006 DBMET00626 | ||
| 0.135 | 0.041 | 0.135 | Protein kinase C gamma inhibitor | 0.115 0.056 DBMET00626 | ||
| 0.113 | 0.022 | 0.116 | mTOR complex 2 inhibitor | 0.116 0.019 DBMET00626 | DBMET00626 | |
| 0.1 | 0.012 | 0.136 | Nicotinic receptor alpha7 subunit antagonist | 0.136 0.008 DBMET00626 | DBMET00626 | |
| 0.174 | 0.086 | 0.174 | P-glycoprotein inhibitor | 0.142 0.13 DBMET00626 | ||
| 0.094 | 0.01 | 0.094 | Dopamine D5 antagonist | 0.057 0.021 DBMET00626 | ||
| 0.228 | 0.145 | 0.239 | Interleukin 2 agonist | 0.239 0.131 DBMET00626 | DBMET00626 | |
| 0.093 | 0.013 | 0.093 | mTOR inhibitor | 0.076 0.019 DBMET00626 | ||
| 0.089 | 0.01 | 0.089 | Nicotinic alpha3beta2 receptor antagonist | 0.082 0.012 DBMET00626 | ||
| 0.088 | 0.01 | 0.088 | Potassium channel (Inward rectifier) blocker | 0.064 0.021 DBMET00626 | ||
| 0.183 | 0.108 | 0.183 | Cyclic AMP phosphodiesterase inhibitor | 0.152 0.15 DBMET00626 | ||
| 0.157 | 0.081 | 0.157 | Sigma receptor agonist | |||
| 0.083 | 0.008 | 0.087 | Mannosidase inhibitor | 0.087 0.007 DBMET00626 | DBMET00626 | |
| 0.11 | 0.043 | 0.11 | mTOR complex 1 inhibitor | 0.098 0.067 DBMET00626 | ||
| 0.172 | 0.107 | 0.19 | Neurotrophic factor enhancer | 0.19 0.087 DBMET00626 | DBMET00626 | |
| 0.09 | 0.026 | 0.09 | Acetylcholine M5 receptor agonist | 0.071 0.043 DBMET00626 | ||
| 0.076 | 0.014 | 0.076 | Nicotinic receptor alpha4 subunit antagonist | 0.046 0.043 DBMET00626 | ||
| 0.084 | 0.023 | 0.084 | Glutamate (mGluR7) antagonist | 0.064 0.054 DBMET00626 | ||
| 0.08 | 0.02 | 0.08 | MDM2 inhibitor | 0.072 0.034 DBMET00626 | ||
| 0.09 | 0.031 | 0.09 | Dopamine agonist | 0.084 0.035 DBMET00626 | ||
| 0.134 | 0.075 | 0.134 | Neurotrophic factor | |||
| 0.151 | 0.093 | 0.151 | Antipruritic | |||
| 0.065 | 0.008 | 0.065 | Vascular adhesion protein 1 inhibitor | 0.063 0.008 DBMET00626 | ||
| 0.067 | 0.01 | 0.067 | Nicotinic receptor beta4 subunit antagonist | |||
| 0.126 | 0.072 | 0.177 | Alpha-N-acetylglucosaminidase inhibitor | 0.177 0.042 DBMET00626 | DBMET00626 | |
| 0.12 | 0.067 | 0.12 | Acetylcholine muscarinic antagonist | |||
| 0.205 | 0.152 | 0.224 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.224 0.108 DBMET00626 | DBMET00626 | |
| 0.14 | 0.089 | 0.14 | Anticoagulant | |||
| 0.085 | 0.035 | 0.254 | Alpha adrenoreceptor agonist | 0.254 0.005 DBMET00626 | DBMET00626 | |
| 0.087 | 0.039 | 0.087 | 5 Hydroxytryptamine 1F antagonist | |||
| 0.075 | 0.027 | 0.075 | Androgen agonist | 0.062 0.038 DBMET00626 | ||
| 0.06 | 0.012 | 0.06 | Guanylate cyclase inhibitor | 0.057 0.014 DBMET00626 | ||
| 0.281 | 0.233 | 0.281 | Antiinflammatory | |||
| 0.068 | 0.021 | 0.108 | 5 Hydroxytryptamine 2 agonist | 0.108 0.008 DBMET00626 | DBMET00626 | |
| 0.09 | 0.043 | 0.103 | Glycine receptor antagonist | 0.103 0.029 DBMET00626 | DBMET00626 | |
| 0.092 | 0.046 | 0.102 | Factor XII inhibitor | 0.102 0.035 DBMET00626 | DBMET00626 | |
| 0.096 | 0.051 | 0.096 | Calcium antagonist | |||
| 0.051 | 0.007 | 0.051 | Cholesterol ester transfer protein antagonist | 0.03 0.024 DBMET00626 | ||
| 0.082 | 0.038 | 0.082 | Benzodiazepine agonist | |||
| 0.109 | 0.067 | 0.109 | Cystathionine beta-synthase inhibitor | |||
| 0.079 | 0.037 | 0.08 | Potassium channel (Tandem pore domain) blocker | 0.08 0.035 DBMET00626 | DBMET00626 | |
| 0.203 | 0.162 | 0.203 | Cholesterol antagonist | |||
| 0.117 | 0.078 | 0.117 | DNA repair enzyme inhibitor | 0.117 0.078 DBMET00626 | ||
| 0.05 | 0.011 | 0.05 | Acetylcholine M4 receptor agonist | |||
| 0.042 | 0.005 | 0.042 | Potassium channel (Inward rectifier) 1 blocker | 0.034 0.012 DBMET00626 | ||
| 0.111 | 0.076 | 0.111 | Alkylator | |||
| 0.039 | 0.005 | 0.046 | Imidazoline I1 receptor antagonist | 0.046 0.004 DBMET00626 | DBMET00626 | |
| 0.175 | 0.142 | 0.186 | RNA-directed DNA polymerase inhibitor | 0.186 0.123 DBMET00626 | DBMET00626 | |
| 0.074 | 0.044 | 0.074 | Orexin receptor 1 antagonist | |||
| 0.077 | 0.047 | 0.077 | Vanilloid 4 agonist | 0.071 0.063 DBMET00626 | ||
| 0.087 | 0.059 | 0.087 | Ca(v)2.2 blocker | 0.084 0.061 DBMET00626 | ||
| 0.092 | 0.065 | 0.098 | Alpha 2d adrenoreceptor antagonist | 0.098 0.052 DBMET00626 | DBMET00626 | |
| 0.055 | 0.03 | 0.055 | Alpha 1L adrenoreceptor antagonist | 0.054 0.033 DBMET00626 | ||
| 0.04 | 0.017 | 0.04 | Ceramide glucosyltransferase inhibitor | |||
| 0.179 | 0.155 | 0.179 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.067 | 0.044 | 0.067 | 5 Hydroxytryptamine 1B antagonist | |||
| 0.05 | 0.027 | 0.052 | Microtubule stabilization | 0.052 0.025 DBMET00626 | DBMET00626 | |
| 0.12 | 0.099 | 0.124 | Cell wall synthesis inhibitor | 0.124 0.094 DBMET00626 | DBMET00626 | |
| 0.054 | 0.034 | 0.054 | 5 Hydroxytryptamine 1B agonist | |||
| 0.099 | 0.079 | 0.101 | Mucolytic | 0.101 0.076 DBMET00626 | DBMET00626 | |
| 0.073 | 0.054 | 0.073 | Acetylcholine M4 receptor antagonist | |||
| 0.048 | 0.029 | 0.048 | Glutamate (mGluR5) agonist | |||
| 0.045 | 0.029 | 0.045 | Nicotinic receptor alpha3 subunit antagonist | |||
| 0.043 | 0.027 | 0.043 | Smo receptor antagonist | |||
| 0.077 | 0.061 | 0.077 | Acetylcholine nicotinic agonist | |||
| 0.1 | 0.085 | 0.101 | Nav1.5 sodium channel blocker | 0.101 0.084 DBMET00626 | DBMET00626 | |
| 0.083 | 0.069 | 0.083 | Bromodomain-containing protein 2 inhibitor | |||
| 0.126 | 0.113 | 0.144 | GABA C receptor rho-2 antagonist | 0.144 0.082 DBMET00626 | DBMET00626 | |
| 0.051 | 0.039 | 0.051 | Protein 50S ribosomal subunit inhibitor | |||
| 0.086 | 0.077 | 0.086 | Sphingomyelinase inhibitor | |||
| 0.05 | 0.041 | 0.05 | Histamine agonist | |||
| 0.068 | 0.059 | 0.068 | Phosphodiesterase VIII inhibitor | |||
| 0.094 | 0.087 | 0.134 | GABA C receptor antagonist | 0.134 0.04 DBMET00626 | DBMET00626 | |
| 0.108 | 0.101 | 0.116 | Antibacterial (Helicobacter pylori) | 0.116 0.088 DBMET00626 | DBMET00626 | |
| 0.193 | 0.187 | 0.193 | Antithrombotic | |||
| 0.058 | 0.052 | 0.058 | 5 Hydroxytryptamine 1D antagonist | |||
| 0.121 | 0.116 | 0.139 | Phospholipase A2 inhibitor | 0.139 0.087 DBMET00626 | DBMET00626 | |
| 0.012 | 0.007 | 0.014 | Imidazoline I2 receptor antagonist | 0.014 0.005 DBMET00626 | DBMET00626 | |
| 0.026 | 0.022 | 0.026 | LFA antagonist | |||
| 0.064 | 0.062 | 0.078 | Secretase beta inhibitor | 0.078 0.039 DBMET00626 | DBMET00626 | |
| 0.042 | 0.04 | 0.042 | Glutamate (mGluR group I) agonist | |||
| 0.108 | 0.106 | 0.108 | Toll-Like receptor antagonist | |||
| 0.032 | 0.03 | 0.032 | Tubulin agonist | |||
| 0.04 | 0.041 | 0.042 | Glutamate (mGluR group III) antagonist | 0.042 0.033 DBMET00626 | DBMET00626 | |
| 0.061 | 0.064 | 0.085 | Glutamate (mGluR6) antagonist | 0.085 0.019 DBMET00626 | DBMET00626 | |
| 0.029 | 0.033 | 0.039 | ATR kinase inhibitor | 0.039 0.014 DBMET00626 | DBMET00626 | |
| 0.116 | 0.123 | 0.152 | MAP3K9 inhibitor | 0.152 0.056 DBMET00626 | DBMET00626 | |
| 0.05 | 0.057 | 0.066 | Glucagon-like peptide 1 agonist | 0.066 0.044 DBMET00626 | DBMET00626 | |
| 0.049 | 0.06 | 0.098 | Alpha 2 adrenoreceptor agonist | 0.098 0.015 DBMET00626 | DBMET00626 | |
| 0.013 | 0.027 | 0.024 | Alpha 2c adrenoreceptor agonist | 0.024 0.007 DBMET00626 | DBMET00626 | |
| 0.12 | 0.134 | 0.152 | Interferon gamma antagonist | 0.152 0.075 DBMET00626 | DBMET00626 | |
| 0.095 | 0.112 | 0.135 | Cyclooxygenase 3 inhibitor | 0.135 0.062 DBMET00626 | DBMET00626 | |
| 0.143 | 0.161 | 0.184 | Immunostimulant | 0.184 0.13 DBMET00626 | DBMET00626 | |
| 0.097 | 0.115 | 0.108 | Cathepsin H inhibitor | 0.108 0.093 DBMET00626 | DBMET00626 | |
| 0.044 | 0.066 | 0.062 | Glucosylceramidase inhibitor | 0.062 0.028 DBMET00626 | DBMET00626 | |
| 0.034 | 0.056 | 0.05 | Kainate receptor agonist | 0.05 0.014 DBMET00626 | DBMET00626 | |
| 0.078 | 0.1 | 0.091 | Expectorant | 0.091 0.079 DBMET00626 | DBMET00626 | |
| 0.036 | 0.059 | 0.043 | CC chemokine 4 receptor antagonist | 0.043 0.04 DBMET00626 | DBMET00626 | |
| 0.072 | 0.096 | 0.089 | NADH dehydrogenase inhibitor | 0.089 0.058 DBMET00626 | DBMET00626 | |
| 0.021 | 0.046 | 0.041 | Motilin receptor antagonist | 0.041 0.007 DBMET00626 | DBMET00626 | |
| 0.064 | 0.091 | 0.106 | Alpha adrenoreceptor antagonist | 0.106 0.053 DBMET00626 | DBMET00626 | |
| 0.08 | 0.108 | 0.118 | AMP-activated protein kinase stimulant | 0.118 0.051 DBMET00626 | DBMET00626 | |
| 0.037 | 0.065 | 0.066 | Toll-Like receptor 8 antagonist | 0.066 0.027 DBMET00626 | DBMET00626 | |
| 0.067 | 0.098 | 0.08 | MAP kinase kinase 7 inhibitor | 0.08 0.048 DBMET00626 | DBMET00626 | |
| 0.014 | 0.047 | 0.036 | Motilin receptor agonist | 0.036 0.008 DBMET00626 | DBMET00626 | |
| 0.012 | 0.048 | 0.02 | Alpha 2b adrenoreceptor agonist | 0.02 0.01 DBMET00626 | DBMET00626 | |
| 0.071 | 0.108 | 0.1 | UDP-glucose 4-epimerase inhibitor | 0.1 0.061 DBMET00626 | DBMET00626 | |
| 0.132 | 0.17 | 0.155 | Antiamyloidogenic | 0.155 0.14 DBMET00626 | DBMET00626 | |
| 0.074 | 0.114 | 0.098 | GABA C receptor rho-1 antagonist | 0.098 0.065 DBMET00626 | DBMET00626 | |
| 0.04 | 0.085 | 0.072 | Toll-Like receptor 7 antagonist | 0.072 0.045 DBMET00626 | DBMET00626 | |
| 0.102 | 0.147 | 0.116 | Papain-like protease (SARS coronavirus) inhibitor | 0.116 0.093 DBMET00626 | DBMET00626 | |
| 0.078 | 0.125 | 0.219 | Amylase inhibitor | 0.219 0.038 DBMET00626 | DBMET00626 | |
| 0.019 | 0.067 | 0.074 | 5 Hydroxytryptamine 2C agonist | 0.074 0.013 DBMET00626 | DBMET00626 | |
| 0.165 | 0.22 | 0.221 | Insulysin inhibitor | 0.221 0.128 DBMET00626 | DBMET00626 | |
| 0.071 | 0.135 | 0.112 | Proteasome inhibitor | 0.112 0.073 DBMET00626 | DBMET00626 | |
| 0.119 | 0.184 | 0.142 | Succinate dehydrogenase inhibitor | 0.142 0.129 DBMET00626 | DBMET00626 | |
| 0.007 | 0.078 | 0.115 | Growth hormone secretagogue receptor agonist | 0.115 0.005 DBMET00626 | DBMET00626 | |
| 0.009 | 0.081 | 0.032 | Arginase inhibitor | 0.032 0.03 DBMET00626 | DBMET00626 | |
| 0.136 | 0.213 | 0.178 | Superoxide dismutase inhibitor | 0.178 0.144 DBMET00626 | DBMET00626 | |
| 0.06 | 0.139 | 0.085 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.085 0.072 DBMET00626 | DBMET00626 | |
| 0.174 | 0.257 | 0.258 | Calcium channel activator | 0.258 0.138 DBMET00626 | DBMET00626 | |
| 0.094 | 0.2 | 0.14 | Adenylate cyclase stimulant | 0.14 0.081 DBMET00626 | DBMET00626 | |
| 0.042 | 0.157 | 0.117 | Adrenaline agonist | 0.117 0.027 DBMET00626 | DBMET00626 | |
| 0.021 | 0.145 | 0.066 | Phenylethanolamine N methyltransferase inhibitor | 0.066 0.005 DBMET00626 | DBMET00626 | |
| 0.005 | 0.13 | 0.023 | Somatostatin 2 agonist | 0.023 0.005 DBMET00626 | DBMET00626 | |
| 0.012 | 0.142 | 0.092 | Somatostatin agonist | 0.092 0.008 DBMET00626 | DBMET00626 | |
| 0.038 | 0.175 | 0.09 | Antiadrenergic | 0.09 0.063 DBMET00626 | DBMET00626 | |
| 0.036 | 0.174 | 0.088 | Adrenaline antagonist | 0.088 0.062 DBMET00626 | DBMET00626 | |
| 0.048 | 0.191 | 0.092 | GABA C receptor agonist | 0.092 0.077 DBMET00626 | DBMET00626 | |
| 0.018 | 0.169 | 0.156 | Somatostatin 4 agonist | 0.156 0.004 DBMET00626 | DBMET00626 | |
| 0.018 | 0.173 | 0.039 | Sphingosine kinase 1 inhibitor | 0.039 0.033 DBMET00626 | DBMET00626 | |
| 0.172 | 0.33 | 0.342 | Calcium channel L-type activator | 0.342 0.123 DBMET00626 | DBMET00626 | |
| 0.027 | 0.187 | 0.061 | Sphingosine kinase inhibitor | 0.061 0.037 DBMET00626 | DBMET00626 | |
| 0.168 | 0.369 | 0.261 | 5 Hydroxytryptamine release inhibitor | 0.261 0.213 DBMET00626 | DBMET00626 | |
| 0.085 | 0.306 | 0.26 | Cardiotonic | 0.26 0.075 DBMET00626 | DBMET00626 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |